A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Who Have Fallen Recently and Have Muscle Weakness
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Landogrozumab (Primary)
- Indications Muscle weakness
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 29 Mar 2015 Results presented at the 2015 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
- 19 Nov 2014 New trial record
- 12 Sep 2014 Primary endpoint Change in appendicular Lean Body Mass has been met, according to an abstract presented at the 36th annual meeting of the American Society for Bone and Mineral Research.